These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34769379)

  • 1. BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation.
    Hoyer S; Eberlein V; Schuler G; Berking C; Heinzerling L; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
    Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS
    Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Tumor Control With MAPK Inhibition in
    Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
    Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells.
    Sanagawa A; Hotta Y; Mori N; Tomita N; Kataoka T; Tohkin M; Kimura K
    Anticancer Drugs; 2021 Nov; 32(10):1076-1083. PubMed ID: 34232935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
    Ott PA; Henry T; Baranda SJ; Frleta D; Manches O; Bogunovic D; Bhardwaj N
    Cancer Immunol Immunother; 2013 Apr; 62(4):811-22. PubMed ID: 23306863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
    Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
    Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.
    Dörrie J; Babalija L; Hoyer S; Gerer KF; Schuler G; Heinzerling L; Schaft N
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29346301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
    Gonzalez-Cao M; Mayo de Las Casas C; Oramas J; Berciano-Guerrero MA; de la Cruz L; Cerezuela P; Arance A; Muñoz-Couselo E; Espinosa E; Puertolas T; Diaz Beveridge R; Ochenduszko S; Villanueva MJ; Basterretxea L; Bellido L; Rodriguez D; Campos B; Montagut C; Drozdowskyj A; Molina MA; Lopez-Martin JA; Berrocal A
    Nat Commun; 2021 Dec; 12(1):7008. PubMed ID: 34853302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of two melanoma cell lines resistant to BRAF/MEK inhibitors (vemurafenib and cobimetinib).
    Kot M; Simiczyjew A; Wądzyńska J; Ziętek M; Matkowski R; Nowak D
    Cell Commun Signal; 2024 Aug; 22(1):410. PubMed ID: 39175042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
    Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
    Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
    Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
    Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular vesicles promote migration despite BRAF inhibitor treatment in malignant melanoma cells.
    Németh A; Bányai GL; Dobos NK; Kós T; Gaál A; Varga Z; Buzás EI; Khamari D; Dank M; Takács I; Szász AM; Garay T
    Cell Commun Signal; 2024 May; 22(1):282. PubMed ID: 38778340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
    Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
    Frederick DT; Piris A; Cogdill AP; Cooper ZA; Lezcano C; Ferrone CR; Mitra D; Boni A; Newton LP; Liu C; Peng W; Sullivan RJ; Lawrence DP; Hodi FS; Overwijk WW; Lizée G; Murphy GF; Hwu P; Flaherty KT; Fisher DE; Wargo JA
    Clin Cancer Res; 2013 Mar; 19(5):1225-31. PubMed ID: 23307859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.